Joseph Schwartz, an analyst from Leerink Partners, maintained the Hold rating on Fulcrum Therapeutics (FULC – Research Report). The associated price target is $4.00.
Joseph Schwartz’s rating is based on several factors influencing Fulcrum Therapeutics’ current position. The company is making progress with its Pociredir Phase 1b trial, particularly in the enrollment of patients for the 12mg and 20mg dose cohorts, with data expected in 2025. This progress is encouraging, especially given the potential for increased fetal hemoglobin levels to reduce acute vaso-occlusive crises, which could significantly impact the treatment landscape.
However, the Hold rating reflects some uncertainties, such as the need to gather more data before potentially broadening the patient pool and market opportunity. The recent withdrawal of Oxbryta has simplified patient enrollment, yet it also highlights the challenges in the advanced therapy space. Additionally, the severity of disease in recruited patients and the ongoing process of site onboarding suggest that while there is promise, there are still hurdles to clear before a more definitive investment stance can be taken.
According to TipRanks, Schwartz is a 5-star analyst with an average return of 12.7% and a 42.74% success rate. Schwartz covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Insmed, and Ascendis Pharma.
In another report released yesterday, H.C. Wainwright also reiterated a Hold rating on the stock with a $4.00 price target.